Expert Interview
Looking at the Future of Oral Weight Loss Medications, Including Structure Therapeutics recent Phase 2 data on Aleniglipron and the Uptake of Novo Nordisks Wegovy
Ticker(s): GPCR, NVO, LLYInstitution: University of California at San Diego
- Board-certified Obesity Medicine Physician and Medical Director for the Weight Management Program at UC San Diego Health
- Treats over 100 patients per year with obesity with a variety of methods including surgery, medication, nutrition, behavior, and lifestyle support.
- Clinical interest in metabolism, weight regulation, treatment of obesity and weight-related medical conditions; Research interests include anti-obesity medications, obesity medicine education and bariatric surgery.
Based on the Phase 2 data, how effective does aleniglipron appear compared to other GLP-1 drugs you use today?
Added By: dami_adminWhat differences do you see in side effects or tolerability between aleniglipron and existing GLP-1 treatments?
Added By: dami_adminWhat concerns, if any, would you have about prescribing aleniglipron based on the data so far?
Added By: dami_adminHow do you see oral weight loss medications fitting into your management of obesity and T2D?
Added By: ben_adminWhat has your uptake of oral wegovy looked like to date?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
